Abbvie Inc (ABBV)

$212.58 -1.18 (-0.55%)
Market Cap 369.98B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 20.65
Forward PE 14.71
Profit Margin 6.91%
Debt to Equity Ratio -11.02
Volume 1,751,556
Avg Vol 6,836,492
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 87%
Beta 0.32
Analysts Strong Sell
Price Target $251.14

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
BillionerOfKing
BillionerOfKing May. 20 at 5:40 PM
$ABBV Current Stock Price: $212.99 Contracts to trade: $212.5 ABBV May 22 2026 Call Entry: $1.99 Exit: $3.56 ROI: 79% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 20 at 5:21 PM
$SLS Must really Gobble SCHLONG being short here now, knowing the 80th EVENT IS COMING and and their Short Lies are worn thin. - 80th EVEN PR WILL LAUNCH THE SHARE PRICE. ps Does Everyone Know BAT/ Best Available Treatment for Control Arm Patients - Aza+VEN Recently Failed 3 Large Phase 3 Trials conducted by $ABBV ? Including Failing 2 For AML Remission Maintenance... this is a $90 Stock trading for $9....
1 · Reply
OnTheBalance
OnTheBalance May. 20 at 5:00 PM
$SLS $LLY $ABBV The 80th Event is NOW Around the Corner.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 20 at 4:51 PM
$SLS The Share Price will continue climbing until the 80th Event PR and then it will Launch - and then We will see ballistic VERTICALITY on the P3 Top Line Results. $60 Share /$11B MCap and there will Still be 4X+ More Upside for Black Rock and Vanguard GPS Immunotherapy will treat 100,000 AML Patients Currently in Remission and Generate Billions of Real Revenue That is Worth Every Nickel of $40B to Big Pharma. $LLY $ABBV This Rigged Manipulated Share Price is offering the Investment Opportunity of Our Lifetimes. in Count Down Mode. - Event rates are not linear, with follow-up ranging from 25 to 62 months. --- 80th Event may have already occurred, waiting to cycle through the data collection process.
1 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 20 at 3:59 PM
$SLS Must really Suck A** being short here now, knowing the 80th EVENT IS COMING and WILL LAUNCH THE SHARE PRICE. ps Does Everyone Know BAT/ Best Available Treatment for Control Arm Patients - Aza+VEN Recently Failed 3 Large Phase 3 Trials conducted by $ABBV ? Including Failing 2 For AML Remission Maintenance... this is a $90 Stock trading for $9....
0 · Reply
NEWBIGTECH
NEWBIGTECH May. 20 at 3:57 PM
$SLS $ABBV $PFE
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 20 at 3:50 PM
$SLS Phase 3 Registrational Results giving Gps the Fda green light to treat 100,000 AML Patients, currently in remission + 40/50,000 more each year - are Coming. - could be any day now. $28B TAM just for AML is worth every nickel of $40B to Big Pharma $ABBV $PFE
0 · Reply
LosersMakeMillions
LosersMakeMillions May. 20 at 1:21 PM
$ABBV $MRK $PFE $SLS this would be amazing 🤩 👇🏽…
0 · Reply
Mike22332233
Mike22332233 May. 20 at 1:07 PM
$SLS UPDATED ... Timeline/Price Prediction: ... SLS will jump to $18-$22 at 80th event ... and then RUN UP TO $55-$60 on GROUNDBREAKING readout results a month later !!! ... from there, it will drift up to the $75-$80 area over the next month ... and soon after, the opening BO Offer will be place at about $140-$160 ... After, a 3 way Bidding War --between $MRK, $PFE, and $ABBV -- the FINAL BO PRICE will be reached at $222 in Q4 of 2026 !!! ... If you agree, LIKE & FOLLOW me 👉 @Mike22332233 as I uncover and post my Special Situation Stocks that have potential for HUGE & QUICK profits ahead ... which I always plow back into more $SLS !!!
1 · Reply
Mike22332233
Mike22332233 May. 19 at 11:56 PM
$SLS UPDATED ... Timeline/Price Prediction: ... SLS will jump to $18-$22 at 80th event ... and then RUN UP TO $55-$60 on GROUNDBREAKING readout results a month later !!! ... from there, it will drift up to the $75-$80 area over the next month ... and soon after, the opening BO Offer will be place at about $140-$160 ... After, a 3 way Bidding War --between $MRK, $PFE, and $ABBV -- the FINAL BO PRICE will be reached at $222 in Q4 of 2026 !!! ... If you agree, LIKE & FOLLOW me 👉 @Mike22332233 as I uncover and post my Special Situation Stocks that have potential for HUGE & QUICK profits ahead ... which I always plow back into more $SLS !!!
1 · Reply
Latest News on ABBV
AbbVie price target lowered to $235 from $236 at Evercore ISI

2026-05-15T12:51:42.000Z - 5 days ago

AbbVie price target lowered to $235 from $236 at Evercore ISI

3 ‘Strong Buy’ Dividend Aristocrat Stocks with 100%+ Payout Ratios, 5/14/26

2026-05-14T20:15:24.000Z - 5 days ago

3 ‘Strong Buy’ Dividend Aristocrat Stocks with 100%+ Payout Ratios, 5/14/26

ABT NEE

AbbVie price target raised to $298 from $294 at Piper Sandler

2026-05-14T11:07:12.000Z - 6 days ago

AbbVie price target raised to $298 from $294 at Piper Sandler

AbbVie Transcript: Bank of America Global Healthcare Conference 2026

May 13, 2026, 2:20 PM EDT - 6 days ago

AbbVie Transcript: Bank of America Global Healthcare Conference 2026

AbbVie Touts Record Sales and Pipeline Momentum at Annual Meeting

May 9, 2026, 10:08 AM EDT - 11 days ago

AbbVie Touts Record Sales and Pipeline Momentum at Annual Meeting

AbbVie Transcript: AGM 2026

May 8, 2026, 10:00 AM EDT - 12 days ago

AbbVie Transcript: AGM 2026

AbbVie to Present at the Bank of America Securities Healthcare Conference

May 6, 2026, 8:00 AM EDT - 14 days ago

AbbVie to Present at the Bank of America Securities Healthcare Conference

AbbVie presented new data across its gastroenterology portfolio at the 2026 DDW

2026-05-05T12:32:52.000Z - 15 days ago

AbbVie presented new data across its gastroenterology portfolio at the 2026 DDW

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

May 5, 2026, 8:05 AM EDT - 15 days ago

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

IBD

AbbVie price target raised to $236 from $232 at Evercore ISI

2026-05-04T12:13:35.000Z - 16 days ago

AbbVie price target raised to $236 from $232 at Evercore ISI

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn't the Beat

May 2, 2026, 8:45 AM EDT - 18 days ago

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn't the Beat

AZN GSK

AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried

May 1, 2026, 3:05 PM EDT - 18 days ago

AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried

Big Pharma M&A set for mega year as patent expiries drive deal urgency

May 1, 2026, 10:03 AM EDT - 19 days ago

Big Pharma M&A set for mega year as patent expiries drive deal urgency

BMY GILD GSK LLY

AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec

Apr 30, 2026, 3:00 PM EDT - 19 days ago

AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec

AbbVie price target raised to $278 from $270 at Morgan Stanley

2026-04-30T18:00:46.000Z - 20 days ago

AbbVie price target raised to $278 from $270 at Morgan Stanley

AbbVie price target raised to $265 from $262 at Canaccord

2026-04-30T13:31:03.000Z - 20 days ago

AbbVie price target raised to $265 from $262 at Canaccord

Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month

Apr 30, 2026, 9:00 AM EDT - 20 days ago

Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month

AbbVie upgraded to Buy at BofA on durable growth

2026-04-30T10:15:57.000Z - 20 days ago

AbbVie upgraded to Buy at BofA on durable growth

AbbVie upgraded to Buy from Neutral at BofA

2026-04-30T10:14:18.000Z - 20 days ago

AbbVie upgraded to Buy from Neutral at BofA

AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?

Apr 29, 2026, 2:50 PM EDT - 20 days ago

AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?

AbbVie raises FY26 revenue view to about $67.3B from about $67B

2026-04-29T16:41:09.000Z - 21 days ago

AbbVie raises FY26 revenue view to about $67.3B from about $67B

AbbVie sees Q2 adjusted EPS $3.74-$3.78, consensus $3.74

2026-04-29T16:39:58.000Z - 21 days ago

AbbVie sees Q2 adjusted EPS $3.74-$3.78, consensus $3.74

AbbVie sees FY26 adjusted gross margin ‘above 84% of sales’

2026-04-29T16:39:07.000Z - 21 days ago

AbbVie sees FY26 adjusted gross margin ‘above 84% of sales’

AbbVie says ‘especially pleased’ with immunology and neuroscience results

2026-04-29T13:25:07.000Z - 21 days ago

AbbVie says ‘especially pleased’ with immunology and neuroscience results

AbbVie Earnings Call Transcript: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 21 days ago

AbbVie Earnings Call Transcript: Q1 2026

AbbVie Earnings release: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 21 days ago

AbbVie Earnings release: Q1 2026

AbbVie Quarterly report: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 21 days ago

AbbVie Quarterly report: Q1 2026

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

Apr 29, 2026, 8:32 AM EDT - 21 days ago

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

Apr 29, 2026, 7:50 AM EDT - 21 days ago

AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

AbbVie Reports First-Quarter 2026 Financial Results

Apr 29, 2026, 7:47 AM EDT - 21 days ago

AbbVie Reports First-Quarter 2026 Financial Results

AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata

Apr 28, 2026, 8:00 AM EDT - 22 days ago

AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata

EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie

Apr 28, 2026, 7:00 AM EDT - 22 days ago

EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie

AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

Apr 27, 2026, 8:05 AM EDT - 23 days ago

AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

US FDA declines to approve AbbVie's wrinkle treatment

Apr 23, 2026, 4:19 PM EDT - 26 days ago

US FDA declines to approve AbbVie's wrinkle treatment

AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.

Apr 23, 2026, 4:05 PM EDT - 26 days ago

AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.

AbbVie to build $1.4 billion manufacturing campus in North Carolina

Apr 22, 2026, 12:59 PM EDT - 4 weeks ago

AbbVie to build $1.4 billion manufacturing campus in North Carolina

AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus

Apr 22, 2026, 12:02 PM EDT - 4 weeks ago

AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

Apr 20, 2026, 2:30 AM EDT - 4 weeks ago

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

Erin Lichy Gets Real About Her Natrelle® Breast Augmentation

Apr 14, 2026, 8:50 AM EDT - 5 weeks ago

Erin Lichy Gets Real About Her Natrelle® Breast Augmentation

Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain

Apr 13, 2026, 2:24 AM EDT - 5 weeks ago

Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain

AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026

Apr 12, 2026, 7:15 AM EDT - 5 weeks ago

AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026

3 Dividend Aristocrats Whose Yields Can Help Combat Inflation

Apr 9, 2026, 2:00 PM EDT - 5 weeks ago

3 Dividend Aristocrats Whose Yields Can Help Combat Inflation

AMCR CVX

AbbVie files lawsuit to address 'outdated' drug discount eligibility program

Apr 8, 2026, 1:38 PM EDT - 6 weeks ago

AbbVie files lawsuit to address 'outdated' drug discount eligibility program

BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year

Apr 8, 2026, 8:00 AM EDT - 6 weeks ago

BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year

The price Americans pay for medicine has gotten horribly out of control. Here's how to fix it.

Apr 7, 2026, 9:53 AM EDT - 6 weeks ago

The price Americans pay for medicine has gotten horribly out of control. Here's how to fix it.

Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin

Apr 7, 2026, 9:00 AM EDT - 6 weeks ago

Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin

Swiss industry body says US tariffs on pharmaceuticals will harm patients

Apr 3, 2026, 11:08 AM EDT - 6 weeks ago

Swiss industry body says US tariffs on pharmaceuticals will harm patients

AMGN AZN BMY MRK NVO

Trump Administration Unveils Up to 100% Tariff on Branded Drugs

Apr 2, 2026, 5:34 PM EDT - 6 weeks ago

Trump Administration Unveils Up to 100% Tariff on Branded Drugs

AZN NVO AMGN BMY MRK

Trump threatens 100% tariff on US drug makers that don't strike deals to lower prices

Apr 2, 2026, 5:33 PM EDT - 6 weeks ago

Trump threatens 100% tariff on US drug makers that don't strike deals to lower prices

AMGN AZN BMY MRK NVO

Drugmakers face 100% tariff unless they cut prices or produce drugs in US

Apr 2, 2026, 3:29 PM EDT - 6 weeks ago

Drugmakers face 100% tariff unless they cut prices or produce drugs in US

AZN NVO AMGN BMY MRK

Global pharma companies that have publicly announced Trump drug pricing agreements

Apr 2, 2026, 2:59 PM EDT - 6 weeks ago

Global pharma companies that have publicly announced Trump drug pricing agreements

AMGN AZN BMY MRK

Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting®

Mar 31, 2026, 8:05 AM EDT - 7 weeks ago

Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting®

AbbVie to Host First-Quarter 2026 Earnings Conference Call

Mar 31, 2026, 8:00 AM EDT - 7 weeks ago

AbbVie to Host First-Quarter 2026 Earnings Conference Call

AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting

Mar 27, 2026, 10:00 AM EDT - 7 weeks ago

AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting

AbbVie Named Official Pharmaceutical Partner of Major League Baseball

Mar 24, 2026, 8:00 AM EDT - 2 months ago

AbbVie Named Official Pharmaceutical Partner of Major League Baseball

AbbVie Proxy statement: Proxy filing

Mar 23, 2026, 8:00 AM EDT - 2 months ago

AbbVie Proxy statement: Proxy filing

AbbVie Proxy statement: Proxy filing

Mar 23, 2026, 8:00 AM EDT - 2 months ago

AbbVie Proxy statement: Proxy filing

US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings

Mar 20, 2026, 12:11 PM EDT - 2 months ago

US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings

AMRX NVS OGN

Buy Or Fear AbbVie Stock At $210?

Mar 19, 2026, 9:26 AM EDT - 2 months ago

Buy Or Fear AbbVie Stock At $210?

Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions

Mar 19, 2026, 3:00 AM EDT - 2 months ago

Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions

TrumpRx lists many medicines at prices higher than paid in UK

Mar 18, 2026, 2:23 PM EDT - 2 months ago

TrumpRx lists many medicines at prices higher than paid in UK

AMGN AZN BMY GILD GSK JNJ LLY

Big drugmakers must face US overcharge claims on medications for low-income patients

Mar 17, 2026, 2:32 PM EDT - 2 months ago

Big drugmakers must face US overcharge claims on medications for low-income patients

AZN NVS SNY

New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row

Mar 13, 2026, 9:00 AM EDT - 2 months ago

New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row

AbbVie Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 11:20 AM EDT - 2 months ago

AbbVie Transcript: Leerink Global Healthcare Conference 2026

AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

Mar 9, 2026, 8:00 AM EDT - 2 months ago

AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

AbbVie Proxy statement: Proxy Filing

Mar 9, 2026, 8:00 AM EDT - 2 months ago

AbbVie Proxy statement: Proxy Filing

These 3 Cash Flow Machines Provide Stability in Uncertain Markets

Mar 6, 2026, 8:26 AM EST - 2 months ago

These 3 Cash Flow Machines Provide Stability in Uncertain Markets

GILD V

AbbVie Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 11:10 AM EST - 2 months ago

AbbVie Transcript: TD Cowen 46th Annual Health Care Conference

AbbVie to Present at the Leerink Partners Global Healthcare Conference

Mar 3, 2026, 8:00 AM EST - 2 months ago

AbbVie to Present at the Leerink Partners Global Healthcare Conference

AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease

Mar 2, 2026, 8:30 AM EST - 2 months ago

AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease

AbbVie to Present at the TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 8:00 AM EST - 3 months ago

AbbVie to Present at the TD Cowen 46th Annual Health Care Conference

AbbVie to invest $380 million to expand US manufacturing in Illinois

Feb 23, 2026, 12:03 PM EST - 3 months ago

AbbVie to invest $380 million to expand US manufacturing in Illinois

AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States

Feb 23, 2026, 11:00 AM EST - 3 months ago

AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States

BillionerOfKing
BillionerOfKing May. 20 at 5:40 PM
$ABBV Current Stock Price: $212.99 Contracts to trade: $212.5 ABBV May 22 2026 Call Entry: $1.99 Exit: $3.56 ROI: 79% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 20 at 5:21 PM
$SLS Must really Gobble SCHLONG being short here now, knowing the 80th EVENT IS COMING and and their Short Lies are worn thin. - 80th EVEN PR WILL LAUNCH THE SHARE PRICE. ps Does Everyone Know BAT/ Best Available Treatment for Control Arm Patients - Aza+VEN Recently Failed 3 Large Phase 3 Trials conducted by $ABBV ? Including Failing 2 For AML Remission Maintenance... this is a $90 Stock trading for $9....
1 · Reply
OnTheBalance
OnTheBalance May. 20 at 5:00 PM
$SLS $LLY $ABBV The 80th Event is NOW Around the Corner.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 20 at 4:51 PM
$SLS The Share Price will continue climbing until the 80th Event PR and then it will Launch - and then We will see ballistic VERTICALITY on the P3 Top Line Results. $60 Share /$11B MCap and there will Still be 4X+ More Upside for Black Rock and Vanguard GPS Immunotherapy will treat 100,000 AML Patients Currently in Remission and Generate Billions of Real Revenue That is Worth Every Nickel of $40B to Big Pharma. $LLY $ABBV This Rigged Manipulated Share Price is offering the Investment Opportunity of Our Lifetimes. in Count Down Mode. - Event rates are not linear, with follow-up ranging from 25 to 62 months. --- 80th Event may have already occurred, waiting to cycle through the data collection process.
1 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 20 at 3:59 PM
$SLS Must really Suck A** being short here now, knowing the 80th EVENT IS COMING and WILL LAUNCH THE SHARE PRICE. ps Does Everyone Know BAT/ Best Available Treatment for Control Arm Patients - Aza+VEN Recently Failed 3 Large Phase 3 Trials conducted by $ABBV ? Including Failing 2 For AML Remission Maintenance... this is a $90 Stock trading for $9....
0 · Reply
NEWBIGTECH
NEWBIGTECH May. 20 at 3:57 PM
$SLS $ABBV $PFE
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 20 at 3:50 PM
$SLS Phase 3 Registrational Results giving Gps the Fda green light to treat 100,000 AML Patients, currently in remission + 40/50,000 more each year - are Coming. - could be any day now. $28B TAM just for AML is worth every nickel of $40B to Big Pharma $ABBV $PFE
0 · Reply
LosersMakeMillions
LosersMakeMillions May. 20 at 1:21 PM
$ABBV $MRK $PFE $SLS this would be amazing 🤩 👇🏽…
0 · Reply
Mike22332233
Mike22332233 May. 20 at 1:07 PM
$SLS UPDATED ... Timeline/Price Prediction: ... SLS will jump to $18-$22 at 80th event ... and then RUN UP TO $55-$60 on GROUNDBREAKING readout results a month later !!! ... from there, it will drift up to the $75-$80 area over the next month ... and soon after, the opening BO Offer will be place at about $140-$160 ... After, a 3 way Bidding War --between $MRK, $PFE, and $ABBV -- the FINAL BO PRICE will be reached at $222 in Q4 of 2026 !!! ... If you agree, LIKE & FOLLOW me 👉 @Mike22332233 as I uncover and post my Special Situation Stocks that have potential for HUGE & QUICK profits ahead ... which I always plow back into more $SLS !!!
1 · Reply
Mike22332233
Mike22332233 May. 19 at 11:56 PM
$SLS UPDATED ... Timeline/Price Prediction: ... SLS will jump to $18-$22 at 80th event ... and then RUN UP TO $55-$60 on GROUNDBREAKING readout results a month later !!! ... from there, it will drift up to the $75-$80 area over the next month ... and soon after, the opening BO Offer will be place at about $140-$160 ... After, a 3 way Bidding War --between $MRK, $PFE, and $ABBV -- the FINAL BO PRICE will be reached at $222 in Q4 of 2026 !!! ... If you agree, LIKE & FOLLOW me 👉 @Mike22332233 as I uncover and post my Special Situation Stocks that have potential for HUGE & QUICK profits ahead ... which I always plow back into more $SLS !!!
1 · Reply
SellasgpsCurativeBAT12
SellasgpsCurativeBAT12 May. 19 at 10:05 PM
$ABBV $ALPMY $NVS $SLS Trading will be halted before any Deal or Data PR! 🙏✌️❤️‍🩹
0 · Reply
TalkMarkets
TalkMarkets May. 19 at 9:49 PM
Dividend Growth Stocks: The Bedrock Of Your Retirement Portfolio $ABBV https://talkmarkets.com/article/dividend-growth-stocks-the-bedrock-of-your-retirement-portfolio-1779227312
0 · Reply
SellasgpsCurativeBAT12
SellasgpsCurativeBAT12 May. 19 at 8:47 PM
$SLS $ABBV $NVS $ALPMY These 4 companies drugs are going to be Obsolete after GPS FDA approval: AbbVie and Genentech: Venclexta (venetoclax) Astellas Pharma: Xospata (gilteritinib) Novartis Pharmaceuticals: Rydapt (midostaurin) Bristol Myers Squibb: Onureg Combined Sellas Platform can treat entire AML from start to finish and will make $10 Billion dollar blockbusters Obsolete. ABBV and Merck will be the biggest looser of the imminent bidding war if they don’t make a move pre- GPS Regal Pivotal Registrational Phase 3 study. SLS GPS will dethrone Merck’s Keytruda as # 1 selling drug on the planet with peek sales of $35 Billion + Mark this post and frame it, Bidding war= $280.00+ 🙏✌️❤️‍🩹
0 · Reply
CaymanStyleBeef
CaymanStyleBeef May. 19 at 3:14 PM
$ABBV $CELH $NKE $RACE good for a red day...diversified gains...stack um up 🤣
0 · Reply
Blockwave1
Blockwave1 May. 19 at 3:14 PM
$ABBV 🩺 $222.5 22 MAY 26 (W) CALL 100 $0.23 ➡️ $0.53 130% GAINER! More wins🔥
1 · Reply
Amscru80
Amscru80 May. 19 at 2:44 PM
$ICCM this is a real gem, news today!! 💎 $SLS $ABBV $PFE $LLY
0 · Reply
Blockwave1
Blockwave1 May. 19 at 2:20 PM
$0.37 on $ABBV here! 60% return! 🔥
0 · Reply
Blockwave1
Blockwave1 May. 19 at 2:18 PM
ADDED HEAVY!!🚨 $ABBV 22 MAY 26 $222.5 CALL $0.23 RELATIVE STRENGTH + SECTOR SENTIMENT + ADDING HEAVY + HIGH CONFIDENCE
0 · Reply
Blockwave1
Blockwave1 May. 19 at 2:17 PM
$ABBV 22 MAY 26 $222.5 CALL $0.23 RELATIVE STRENGTH + SECTOR SENTIMENT + ADDING HEAVY + HIGH CONFIDENCE
0 · Reply
Amscru80
Amscru80 May. 19 at 2:03 PM
$ICCM buy now or cry later, with great news!!! 🚀🚀🚀 $SLS $LLY $ABBV $CGON
0 · Reply
Mike22332233
Mike22332233 May. 19 at 12:04 PM
$SLS UPDATED ... Timeline/Price Prediction: ... SLS will jump to $18-$22 at 80th event ... and then RUN UP TO $55-$60 on GROUNDBREAKING readout results a month later !!! ... from there, it will drift up to the $75-$80 area over the next month ... and soon after, the opening BO Offer will be place at about $140-$160 ... After, a 3 way Bidding War --between $MRK, $PFE, and $ABBV -- the FINAL BO PRICE will be reached at $222 in Q4 of 2026 !!! ... If you agree, LIKE & FOLLOW me 👉 @Mike22332233 as I uncover and post my Special Situation Stocks that have potential for HUGE & QUICK profits ahead ... which I always plow back into more $SLS !!!
2 · Reply
Mike22332233
Mike22332233 May. 19 at 12:36 AM
$SLS SPOT ON — and exactly what many of us have been saying for over a year now !!! … and much of this is what I based my BO final price in a bidding war (between $MRK, $PHE, $ABBV) to be $222 !!!! FOLLOW me 👉 @Mike22332233 as I uncover and post my Special Situation Stocks that have potential for HUGE & QUICK profits ahead ... which I always plow back into more $SLS !!!
0 · Reply